162 related articles for article (PubMed ID: 20402658)
21. Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors.
Maccari R; Ottanà R; Curinga C; Vigorita MG; Rakowitz D; Steindl T; Langer T
Bioorg Med Chem; 2005 Apr; 13(8):2809-23. PubMed ID: 15781392
[TBL] [Abstract][Full Text] [Related]
22. Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection.
Nantasenamat C; Monnor T; Worachartcheewan A; Mandi P; Isarankura-Na-Ayudhya C; Prachayasittikul V
Eur J Med Chem; 2014 Apr; 76():352-9. PubMed ID: 24589490
[TBL] [Abstract][Full Text] [Related]
23. Kinetic and molecular docking studies of loganin and 7-O-galloyl-D-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase.
Lee CM; Jung HA; Oh SH; Park CH; Tanaka T; Yokozawa T; Choi JS
Arch Pharm Res; 2015 Jun; 38(6):1090-8. PubMed ID: 25315636
[TBL] [Abstract][Full Text] [Related]
24. Induced fit docking, pharmacophore modeling, and molecular dynamic simulations on thiazolidinedione derivatives to explore key interactions with Tyr48 in polyol pathway.
Vijjulatha M; Lingala Y; Merugu RT
J Mol Model; 2014 Jul; 20(7):2348. PubMed ID: 24974084
[TBL] [Abstract][Full Text] [Related]
25. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
Bhadada SV; Vyas VK; Goyal RK
Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
[TBL] [Abstract][Full Text] [Related]
26. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
[TBL] [Abstract][Full Text] [Related]
27. Self-organizing molecular field analysis on human β-secretase nonpeptide inhibitors: 5, 5-disubstituted aminohydantoins.
Li Z; Zhou M; Wu F; Li R; Ding Z
Eur J Med Chem; 2011 Jan; 46(1):58-64. PubMed ID: 21093114
[TBL] [Abstract][Full Text] [Related]
28. In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors.
Maccari R; Del Corso A; Giglio M; Moschini R; Mura U; Ottanà R
Bioorg Med Chem Lett; 2011 Jan; 21(1):200-3. PubMed ID: 21129963
[TBL] [Abstract][Full Text] [Related]
29. 3D-QSAR studies on a series of dihydroorotate dehydrogenase inhibitors: analogues of the active metabolite of leflunomide.
Li SL; He MY; Du HG
Int J Mol Sci; 2011; 12(5):2982-93. PubMed ID: 21686163
[TBL] [Abstract][Full Text] [Related]
30. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
[TBL] [Abstract][Full Text] [Related]
31. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
Huang Q; Liu Q; Ouyang D
Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
[TBL] [Abstract][Full Text] [Related]
32. Quantitative structure-activity relationship of spirosuccinimide type aldose reductase inhibitors diminishing sorbitol accumulation in vivo.
Ko K; Won H; Won Y
Bioorg Med Chem; 2006 May; 14(9):3090-7. PubMed ID: 16412651
[TBL] [Abstract][Full Text] [Related]
33. Aldose Reductase: a cause and a potential target for the treatment of diabetic complications.
Thakur S; Gupta SK; Ali V; Singh P; Verma M
Arch Pharm Res; 2021 Jul; 44(7):655-667. PubMed ID: 34279787
[TBL] [Abstract][Full Text] [Related]
34. Self-organizing molecular field analysis on pregnane derivatives as human steroidal 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Bhardwaj TR; Kumar M
Steroids; 2010 Jun; 75(6):411-8. PubMed ID: 20170668
[TBL] [Abstract][Full Text] [Related]
35. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
Suzen S; Buyukbingol E
Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
[TBL] [Abstract][Full Text] [Related]
36. A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors.
Hu L; Chen G; Chau RM
J Mol Graph Model; 2006 Jan; 24(4):244-53. PubMed ID: 16226911
[TBL] [Abstract][Full Text] [Related]
37. Search for non-acidic ALR2 inhibitors: Evaluation of flavones as targeted agents for the management of diabetic complications.
Vyas B; Choudhary S; Singh PK; Kumar M; Verma H; Singh M; Malik AK; Silakari O
Bioorg Chem; 2020 Mar; 96():103570. PubMed ID: 31978681
[TBL] [Abstract][Full Text] [Related]
38. Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors.
Balestri F; Quattrini L; Coviello V; Sartini S; Da Settimo F; Cappiello M; Moschini R; Del Corso A; Mura U; La Motta C
Cell Chem Biol; 2018 Nov; 25(11):1414-1418.e3. PubMed ID: 30122369
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and activity of a new series of (Z)-3-phenyl-2-benzoylpropenoic acid derivatives as aldose reductase inhibitors.
Wang SJ; Yan JF; Hao D; Niu XW; Cheng MS
Molecules; 2007 Apr; 12(4):885-95. PubMed ID: 17851441
[TBL] [Abstract][Full Text] [Related]
40. Substituted derivatives of indole acetic acid as aldose reductase inhibitors with antioxidant activity: structure-activity relationship.
Juskova M; Majekova M; Demopoulos V; Stefek M
Gen Physiol Biophys; 2011 Dec; 30(4):342-9. PubMed ID: 22131315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
